Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.

Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A.

Leuk Lymphoma. 2011 Dec;52(12):2237-53. doi: 10.3109/10428194.2011.596963. Epub 2011 Aug 10.

PMID:
21827361
2.
3.
4.

PEG-asparaginase.

Fu CH, Sakamoto KM.

Expert Opin Pharmacother. 2007 Aug;8(12):1977-84. Review.

PMID:
17696798
5.

Pegasparaginase: where do we stand?

Zeidan A, Wang ES, Wetzler M.

Expert Opin Biol Ther. 2009 Jan;9(1):111-9. doi: 10.1517/14712590802586058 . Review.

PMID:
19063697
6.

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.

Hijiya N, van der Sluis IM.

Leuk Lymphoma. 2016;57(4):748-57. doi: 10.3109/10428194.2015.1101098. Epub 2015 Nov 20. Review.

7.

Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.

Beaupin LK, Bostrom B, Barth MJ, Franklin I, Jaeger R, Kamath P, Schreiber B, Bleyer A.

Leuk Lymphoma. 2017 Apr;58(4):766-772. doi: 10.1080/10428194.2016.1218004. Epub 2016 Sep 19. Review.

PMID:
27643446
8.

Peg-asparaginase for acute lymphoblastic leukemia.

Rytting M.

Expert Opin Biol Ther. 2010 May;10(5):833-9. doi: 10.1517/14712591003769808. Review.

PMID:
20345338
9.

Pegaspargase: a review of clinical studies.

Graham ML.

Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302. Review.

PMID:
14499708
10.

Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review.

Oparaji JA, Rose F, Okafor D, Howard A, Turner RL, Orabi AI, Byersdorfer C, Mi Q, Ritchey K, Lowe ME, Husain SZ.

J Clin Gastroenterol. 2017 Nov/Dec;51(10):907-913. doi: 10.1097/MCG.0000000000000827. Review.

PMID:
28375864
11.

L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.

Kumar K, Kaur J, Walia S, Pathak T, Aggarwal D.

Leuk Lymphoma. 2014 Feb;55(2):256-62. doi: 10.3109/10428194.2013.803224. Epub 2013 Jun 14. Review.

PMID:
23662993
12.

[Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].

Thomas X, Cannas G, Chelghoum Y, Gougounon A.

Bull Cancer. 2010 Sep;97(9):1105-17. doi: 10.1684/bdc.2010.1168. Review. French.

13.

Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.

Burke MJ, Rheingold SR.

Leuk Lymphoma. 2017 Mar;58(3):540-551. doi: 10.1080/10428194.2016.1213826. Epub 2016 Aug 22. Review.

PMID:
27546298
14.

Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.

Raetz EA, Salzer WL.

J Pediatr Hematol Oncol. 2010 Oct;32(7):554-63. doi: 10.1097/MPH.0b013e3181e6f003. Review.

PMID:
20724951
15.

Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.

Hasan H, Shaikh OM, Rassekh SR, Howard AF, Goddard K.

Pediatr Blood Cancer. 2017 Jan;64(1):81-88. doi: 10.1002/pbc.26200. Epub 2016 Aug 31. Review.

PMID:
27578304
16.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.

Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP.

Ann N Y Acad Sci. 2014 Nov;1329:81-92. doi: 10.1111/nyas.12496. Epub 2014 Aug 5. Review.

17.

The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia.

Truelove E, Fielding AK, Hunt BJ.

Leukemia. 2013 Mar;27(3):553-9. doi: 10.1038/leu.2012.290. Epub 2012 Oct 9. Review.

PMID:
23099335
18.

Expanding targets for a metabolic therapy of cancer: L-asparaginase.

Covini D, Tardito S, Bussolati O, Chiarelli LR, Pasquetto MV, Digilio R, Valentini G, Scotti C.

Recent Pat Anticancer Drug Discov. 2012 Jan;7(1):4-13. Review.

PMID:
21854356
19.

Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Banerji J.

Int J Mol Med. 2015 Sep;36(3):607-26. doi: 10.3892/ijmm.2015.2285. Epub 2015 Jul 15. Review.

20.

Asparaginase pharmacology: challenges still to be faced.

Lanvers-Kaminsky C.

Cancer Chemother Pharmacol. 2017 Mar;79(3):439-450. doi: 10.1007/s00280-016-3236-y. Epub 2017 Feb 14. Review.

PMID:
28197753

Supplemental Content

Support Center